Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVEC Trial: Antihypertensives for Cognitive Impairment
NCT00605072Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2008
- Primary completion
- Dec 2011
- Countries
- 1
- Sponsor
- University of Southern California
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Conditions
- cognitive impairmenthypertension (HTN)
01
Overview
Phase 2, randomised, double-blind trial of candesartan and lisinopril in cognitive impairment and hypertension (HTN), sponsored by University of Southern California. Started Jan 2008; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Elderly patients (60+) with hypertension and objective cognitive impairment (CLOX1 score <= 10 or memory subtest <= 1 SD). Excludes patients with CHF, diabetes, or recent stroke.
04
Registry description
The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.
Beyond the preview
Go deeper on NCT00605072.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605072.